Jiangsu Hengrui Pharmaceuticals Co.,Ltd (1276.HK)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in HKD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | HKD bn | 31 | 31 | 24 | 25 | 30 | 35 | 35 | 39 |
| Operating profit | HKD bn | 10 | 9 | ||||||
| Net profit | HKD bn | 7 | 5 | 4 | 5 | 7 | 9 | 9 | 11 |
| EPS reported | HKD | 1.31 | 1.31 | ||||||
| Operating cashflow per share | HKD | 1.93 | 1.36 | ||||||
| Capex per share | HKD | 0.51 | 0.50 | ||||||
| FCF per share | HKD | 1.42 | 0.86 | ||||||
| Free cash flow | HKD bn | 9 | 6 | ||||||
| Net debt | HKD bn | -46 | -44 | ||||||
| Book value equity | HKD bn | 68 | 75 | ||||||
| Book value per share | HKD | 10.43 | 11.29 | ||||||
| Number of shares | m | 6,534.79 | 6,600.54 | ||||||
| DPS (TTM paid) | HKD | 0.23 | 0.23 |
Financial summary
Financials in HKD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 54.50 | 34.19 | ||||||
| P/B LTM | x | 6.79 | 6.21 | ||||||
| P/S LTM | x | 13.15 | 13.20 | ||||||
| P/FCF LTM | x | 50.27 | 73.23 | ||||||
| EV/EBITDA LTM | x | 39.19 | 44.82 | ||||||
| EV/Sales LTM | x | 11.85 | 8.16 | ||||||
| Earnings Yield LTM | % | +1.83% | +2.92% | ||||||
| FCF Yield | % | +1.99% | +1.37% | ||||||
| Quality | |||||||||
| ROE | % | +12.58% | +12.42% | ||||||
| ROIC | % | +12.55% | +10.01% | ||||||
| Operating margin | % | +28.42% | +23.92% | ||||||
| Gross margin | % | +86.21% | +85.34% | ||||||
| FCF/Sales | % | +26.16% | +18.16% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +23.58% | +23.58% | ||||||
| Sales Growth YoY | % | +18.20% | +17.78% | ||||||
| Net Income Growth YoY | % | +27.26% | +28.81% | ||||||
| FCF Growth | % | +58.65% | +8.90% | ||||||
| Operating Profit Growth | % | +25.51% | +7.04% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +0.31% | +0.43% | ||||||
| Dividend Growth | % | +6.66% | +6.66% | ||||||
| Payout Ratio | % | +16.69% | +15.72% | ||||||
| FCF/Debt | x | 191.04 | 7.55 | ||||||
| Net Debt/EBITDA | x | -4.28 | -4.43 | ||||||
| EBIT/Net interest | x | 626.53 | 1,317.81 | ||||||
| Net debt/market cap | % | 0.00% | +0.23% | ||||||
| Net debt/Equity | x | -0.67 | -0.59 | ||||||
| Gross debt/equity | x | 0.00 | 0.01 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Jiangsu Hengrui Pharmaceuticals Co.,Ltd (1276.HK)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free